The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups

de Witte, T; Suciu, S; van Dijk, J; Delforge, Michel; Hagemeijer-Hausman, Anne; Jotterand-Bellomo, M; Tigaud, I; Belhabri, A; Aul, C; Avaido, M; Selleslag, D; Schouten, H; Ferrant, A; Amadori, S; Muus, P; Anak, O; Gratwohl, A; Willemze, R

Blood

The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups

Author:

de Witte, T

Suciu, S ; van Dijk, J ; Delforge, Michel ; Hagemeijer-Hausman, Anne ; Jotterand-Bellomo, M ; Tigaud, I ; Belhabri, A ; Aul, C ; Avaido, M ; Selleslag, D ; Schouten, H ; Ferrant, A ; Amadori, S ; Muus, P ; Anak, O ; Gratwohl, A ; Willemze, R

Keywords:

Science & Technology, Life Sciences & Biomedicine, Hematology, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1114 Paediatrics and Reproductive Medicine, Immunology, 3101 Biochemistry and cell biology, 3201 Cardiovascular medicine and haematology, 3213 Paediatrics

Blood The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups

Author:

Keywords:

Blood

The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups